Apolipoprotein B and A-I: Cardiovascular risk factor?;Apolipoproteínas B e A-I: Fatores de risco cardiovascular?

Revista da Associacao Medica Brasileira

Volumn 53, Issue 3, 2007, Pages 276-282

  Forti, Neusa ^a,b   Diament, Jayme ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Apolipoprotein; Cardiovascular disease; Risk factor

Indexed keywords

EID: 34547652172     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0104-42302007000300029     Document Type: Article

References (40)

1. Executive Summary of the Third Report of National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation and Treatment of High. Blood cholesterol in adults (adult treatment Panel III). JAMA. 2001;285(19):2486-97.
2. III Diretrizes Brasileiras sobre Dislipidemia e Diretriz de Prevenção da Aterosclerose. Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2001;77(supl 3):1-48.
3. Barter PJ, Ballantyne CM, Carmena R, Cabezaz MC, Chapman MJ, Couture P, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty - person/ten - country panel. J Intern Med. 2006;259(3):247-58.
4. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid modifying therapy. J Intern Med. 2004;255(2):188-205.
5. Sniderman AD, Furberg CD, Keech A, Van Lennep JE, Frolich J, Jungner I, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet. 2003;361(9359):777-80.
6. Denke MA. Weighing in before the fight: low-density lipoprotein cholesterol and non-high density lipoprotein cholesterol versus apolipoprotein B as the predictor for coronary heart disease and the best measure of therapy. Circulation. 2005;112(22):3368-70.
7. Bachorick PS, Lovejog KL, Carrol MD, Johnson CL. Apolipoprotein B and A-I distributions in the United States, 1988-1991: results of the National Health and Nutrition Examination Survey III (NHANES III) Clin Chem. 1997;43(12):2364-78.
8. Sniderman AD, St Pierre AC, Cantin B, Dagenais G, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of artherosclerotic risk. Am J Cardiol. 2003;91(10):1173-7.
9. Sinderman AD. Apolipoprotein B versus non-high- density lipoprotein cholesterol. And the winner is. Circulation. 2005;112:(22):3366-7.
10. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein B values by use of international reference material. Clin Chem. 1994;40(4):586-92.
11. Oram JF, Vaughan AM. ABCA1- Mediated transport of cellular cholesterol to HDL and lipoproteins. Curr Opin Lipidol. 2000;11(3):253-60.
12. Forti N, Diament J. Lipoproteínas de alta densidade (HDL): aspectos metabólicos, clínicos, epidemológicos e de intervenção terapêutica. Atualização para os clínicos. Arq Bras Cardiol. 2006;87(5):671-9.
13. Marcovina SM, Albers JJ, Henderson LO, Hannan WH. International Federation of Clinical Chemistry standardization project of measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem. 1993;39(5):773-81.
14. Walldius G, Jungner I. Rationale for using apolipoprotein B and apolipoprotein A-I as indicators of cardiac risk and as target for lipid-lowering therapy. Eur Heart J. 2005;26(3):210-2.
15. Freedman DS, Scrinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS. The relation of apolipoproteins A-I and B in children to parental myocardial infarction . N Engl J Med. 1986;315(12):721-6.
16. Lamarche B, Moorjani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94(3):273-8.
17. St. Pierre AC, Cantin B, Dagenais G, Després JP, Lamarche B. Apolipoprotein B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am J Cardiol. 2006;97(7):997-1001.
18. Bolibar I, Van Eckardstein A, Assman G, Thompson E. Short-term prognostic value of lipid measurement in patients with angina pectoris. The ECAT Angina Pectoris Study Group: European Concerted Action on Thrombosis and Disabilities. Thromb Haemost. 2000;84(6):955-60.
19. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I and improvement in the prediction of fatal myocardial infarctuion (AMORIS study): a prospective study. Lancet. 2001;358(9138):2026-33.
20. Walldius G, Jungner I, Aastveit AH, Holme I, Furberg CD, Sniderman AD. The apo B/apo A-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med. 2004;42(12):1355-63.
21. Walldius G, Aastveit AH, Jungner I.Stroke mortality and the apo B/apoAI ratio: results of the AMORIS prospective study. J Intern Med. 2006;295(3):259-66.
22. Jungner I, Sniderman AD, Furberg CD, Aastveid AH, Holme I, Walldius G. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction? J Am Cardiol. 2006;97(7):943-6.
23. Sharret AR, Ballantyne CM, Coady AS, Heiss G, Sorlie PD, Catellier D, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoprotein A-I and B, and HDL subfractions. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104(10):1108-13.
24. Talmud P, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease in middle - aged UK men. Arterioscler Thromb Vasc Biol. 2002;22(11):1918-23.
25. Meisinger C, Loewell H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women : results from the Monica / Kora Augsburg cohort study. Eur Heart J. 2004;26(3):271-8.
26. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the InterHeart Study): case - control study Lancet. 2004;364(9438):937-52.
27. Pischon T, Girman CJ, Sacks FM, Rifar N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112(22):3375-83.
28. Ridker PM, Rifai N, Cook N, Bradwin GBS, Buring JE. Non HDL cholesterol, apolipoproteins A-I and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disiase in women JAMA. 2005;294(3):326-33.
29. Jiang R, Schulze M, Li T, Nader R, Stampfer MJ, Rimm EB, et al. Non HDL cholesterol and apolipoprotein B predict cardiovascular disease events among type 2 diabetes. Diabetes Care. 2004;27(8):1991-7.
30. Williams K, Sniderman AD, Sattar N, D'Agostino R, Wagenknekt LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2003;108(19):2312-6.
31. Sattar N, Willians K, Sniderman AD, D' Agostino R, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with metabolic syndrome in the Insulin Resistence Atherosclerosis Study. Circulation. 2004;110(17):2687-93.
32. - Lind L, Vessby B, Sundstrom J. The apolipoprotein B/A-I ratio and metabolic syndrome independently predict risk for myocardial infarction in middle-aged men Arterioscler Thromb Vasc Biol. 2006;26(2):406-10.
33. Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weiss S, et al. Relation between baseline and on treatment lipid parameters and first acute major coronary events in the Air Force / Texas Coronary Atherosclerosis Prevention Study (AFCAPS / Tex CAPS). Circulation. 2000;101(5):477-86.
34. Pedersen TJ, Olsson AG, Faergeman O, Kjekskus J, Wedel H, Berg C, et al. Lipoproteins changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatim Survival study (4S). Circulation 1998;97(15):1453-60.
35. Simes RJ, Marschner IC, Hunt D, Colghon D, Sullivan D, Stewart RH. Relationship between lipid levels and clinical out comes in the Long-term Intervention with Pravastatin in the Ischemic Disease (LIPID) Trial : to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation. 2002;105(10):1162-9.
36. Brown BG, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, et al. Regression of coronary artery disease as a result of intensive lipid: lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-98.
37. Van Lennep JER, Westerveld HT, Van Lennep HWOR, Zwinderman AH, Erkelens DW, Vander Wall EE. Apolipoprotein concentration during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol. 2000;20(11):2408-13.
38. Grundy SM. Low density lipoprotein, non-high density lipoprotein and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002;106(20):2526-9.
39. Grundy SM, Cleeman JJ, Merz HB, Brewer JR HB, Clarck LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation. 2004;110(2):227-39.
40. Stein EA, Sniderman A, Laskarzenski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high- density lipoprotein cholesterol, or apolipoprotein B Am J Cardiol 2005; 96 (9) Suppl 1: 36-43.